Research progress of indole compounds with potential antidiabetic activity
Yuqian Zhu1, Jinran Zhao1, Longbiao Luo1
1School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, 710061, China.
European Journal of Medicinal Chemistry
|June 30, 2021
Summary
Indole compounds, both natural and synthetic, show promise as novel antidiabetic agents. This review details their structures, synthesis, and mechanisms for combating the global diabetes epidemic.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Natural Products Chemistry
Background:
- Diabetes mellitus is a growing global epidemic requiring novel therapeutic agents.
- Indole alkaloids, found in nature, exhibit diverse biological activities, including antidiabetic effects.
- Synthetic indole derivatives mimic natural compounds and are actively explored for medicinal applications.
Purpose of the Study:
- To comprehensively review indole compounds with potential antidiabetic activity.
- To classify indole structures, including natural alkaloids and synthetic derivatives.
- To summarize isolation/synthesis methods and discuss antidiabetic mechanisms.
Main Methods:
- Literature review focusing on indole compounds and their antidiabetic properties.
- Classification of compounds based on structural features.
- Summary of isolation and synthetic approaches.
- Discussion of documented antidiabetic effects and mechanisms of action.
Main Results:
- Indole alkaloids and their synthetic analogs possess significant potential as antidiabetic drugs.
- A wide array of indole structures have been identified and synthesized for antidiabetic research.
- Various mechanisms of action contribute to the antidiabetic effects of these compounds.
Conclusions:
- Indole derivatives represent a promising scaffold for the development of new antidiabetic medications.
- Further research into the synthesis and biological evaluation of indole compounds is warranted.
- Understanding the structure-activity relationships can accelerate the discovery of effective diabetes treatments.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
312
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
312
Insulin: Biosynthesis, Chemistry, and Preparation
724
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
724
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
344
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
344
Oral Hypoglycemic Agents: Biguanides and Glitazones
378
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
378
Glucagon-like Receptor Agonists
504
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
504
Oral Hypoglycemic Agents: Glinides
338
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
338


